目的:对比UBE-TLIF与MIS-TLIF在治疗单节段LSS的临床疗效。方法:对2019年01月至2021年09月收治的87例单节段LSS患者,A组43例行UBE-TLIF手术,B组44例行MIS-TLIF手术。分析对比两组患者手术时间、术中预估出血量、住院时间、手术并发症、术后伤口VAS评分、ODI评分。结果:在手术时间上,A组显著优于B组(P 0.05)。两组患者在术后早期24 h、48 h术后伤口VAS评分存在区别(P 0.05)。2组患者术后1月、3月、6月、末次随访ODI评分较术前均明显改善(P 0.05)。A组并发症发生率为11.6% (5/43),B组并发症发生率为13.6% (6/44),差异无统计学意义(P > 0.05)。结论:两种技术在治疗单节段LSS均可获得良好的临床疗效,相比MIS-TLIF技术,UBE-TLIF技术具有操作灵活,节约时间等优点。Objective: To compare the clinical efficacy of UBE-TLIF with MIS-TLIF in the treatment of LSS in a single segment. Methods: A total of 87 patients with single-segment LSS who were admitted from January 2019 to September 2021 were treated, group A 43 routine UBE-TLIF surgery, Group B 44 routine MIS-TLIF surgery. The analysis compared the time of operation, estimated bleeding amount during surgery, hospitalization time, surgical complications, VAS score of postoperative wound and ODI score of two groups of patients. Results: Group A was significantly better than Group B (P 0.05). There was a difference in VAS scores for wounds 24 h, 48 h early after surgery (P 0.05). The ODI scores of the two groups were significantly improved at 1 month, 3 months, 6 months and the last follow-up after operation (P 0.05). The complication rate was 11.6% (5/43) in group A and 13.6% (6/44) in group B. But there was no statistical significance between groups (P > 0.05). Conclusion: Both UBE-TLIF and MIS-TLIF have good clinical efficacy in the treatment of single-level LSS, but UBE-TLIF has the advantages of flexible operation and time saving.
肺癌的发病率逐年上升,已成为全球范围内致死率最高的恶性肿瘤之一。咯血是肺癌患者常见且危及生命的严重并发症,严重影响患者的生活质量和预后。对于大咯血的肺癌患者,内科常规治疗往往疗效不佳,外科手术的创伤较大且并发症多,而支气管动脉化疗栓塞术(BACE)作为一种有效的局部微创治疗手段,广泛应用于肺癌咯血患者。目前支气管动脉化疗栓塞术已较为成熟,治疗肺癌咯血安全有效,本文对支气管动脉化疗栓塞术在肺癌咯血治疗中的应用进行综述,论述最新的治疗进展,为临床实践提供参考。The incidence of lung cancer is increasing year by year and has become one of the most lethal malignant tumors worldwide. Hemoptysis is a common and life-threatening complication in lung cancer patients, which seriously affects their quality of life and prognosis. For patients with hemoptysis, conventional medical treatment is often ineffective, and surgery is more traumatic and has many complications. As an effective local minimally invasive treatment, bronchial artery chemoembolization (BACE) is widely used in patients with hemoptysis of lung cancer. At present, bronchial artery chemoembolization has become more mature, safe and effective in the treatment of hemoptysis in lung cancer. This article reviews the application of bronchial artery chemoembolization in the treatment of hemoptysis in lung cancer, discusses the latest therapeutic advances, and provides references for clinical practice.
暂无评论